ArticleMolecular biology reports2026
Differential expression of PPAR isoforms in streptozotocin induced model of sporadic alzheimer's disease in zebrafish.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundSporadic Alzheimer's Disease (sAD) is a multifactorial neurodegenerative disorder in which metabolic dysfunctions and central insulin resistance are recognized as key pathogenic drivers accompanied by amyloid and tau pathology. Effective disease-modifying therapies remain elusive, representing a major global public health concern. Peroxisome proliferator-activated receptors (PPARs) have emerged as promising therapeutic targets due to their roles in regulating neuroinflammation, lipid metabolism and insulin sensitivity. Despite extensive studies highlighting the distinct role of PPAR isoforms in neurodegeneration, their involvement in sAD pathology remains unexplored.
methodsThe role of PPARs was evaluated in streptozotocin (STZ) model of sAD. STZ was administered intracerebroventricularly at a dose of 5 mg/kg for 7 days. The cognitive functions and expression of PPAR isoforms and its downstream targets were investigated in adult zebrafish.
resultsSTZ-treated zebrafish exhibited significant cognitive impairment with decreased preference for the novel object indicating working memory deficits. Molecular analysis revealed isoform-specific modulation of PPARs. PPARα was upregulated, whereas its downstream targets (acox1, cpt1, map3k8) were downregulated suggesting impaired transcriptional activation. PPARγ, PPARβ/δ and their targets were significantly downregulated at both transcript and protein levels suggesting suppression of their neuroprotective functions. Immunofluorescence revealed distinct spatial localization patterns; PPARα was prominent in telencephalon and optic tectum; PPARγ showed punctate nuclear expression in preoptic area; and PPARβ/δ displayed diffuse nuclear staining in diencephalon.
conclusionsThese findings demonstrate that STZ-induced cognitive deficits are accompanied by region-specific dysregulation in expression of PPAR isoforms suggesting that PPAR modulation may be a therapeutic strategy to prevent sAD pathogenesis.
Indexed as
Identifiers
42213199What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.